The Emerging Molecular Diagnostics Industry:
Kellogg School of Management
The Emerging Molecular Diagnostics Industry: Applera’s Path to a Leadership Role
June 5, 2003
By John Fadlovich Carl Finamore Jodi Flax Kevin Lynch Rebecca Wildman
Applera Corporation in the Molecular Diagnostics Industry
Table of Contents
1. 2. Introduction................................................................................................................. 1 Industry Overview ...................................................................................................... 1 2.1. In Vitro Diagnostics............................................................................................ 1 2.2. Molecular Diagnostics ........................................................................................ 2 2.3. Competitive landscape ........................................................................................ 3 3. Applera Corporation ................................................................................................... 5 3.1. Organizational Overview .................................................................................... 5 3.1.1. Applied Biosystems (ABI).......................................................................... 5 3.1.2. Celera Genomics......................................................................................... 5 3.1.3. Celera Diagnostics ...................................................................................... 6 3.2. Intellectual Property............................................................................................ 6 4. Commercialization Environment ................................................................................ 7 4.1. Appropriability.................................................................................................... 7 4.2. Complementary Assets ....................................................................................... 7 4.2.1. Strategic
The Emerging Molecular Diagnostics Industry: Applera’s Path to a Leadership Role
June 5, 2003
By John Fadlovich Carl Finamore Jodi Flax Kevin Lynch Rebecca Wildman
Applera Corporation in the Molecular Diagnostics Industry
Table of Contents
1. 2. Introduction................................................................................................................. 1 Industry Overview ...................................................................................................... 1 2.1. In Vitro Diagnostics............................................................................................ 1 2.2. Molecular Diagnostics ........................................................................................ 2 2.3. Competitive landscape ........................................................................................ 3 3. Applera Corporation ................................................................................................... 5 3.1. Organizational Overview .................................................................................... 5 3.1.1. Applied Biosystems (ABI).......................................................................... 5 3.1.2. Celera Genomics......................................................................................... 5 3.1.3. Celera Diagnostics ...................................................................................... 6 3.2. Intellectual Property............................................................................................ 6 4. Commercialization Environment ................................................................................ 7 4.1. Appropriability.................................................................................................... 7 4.2. Complementary Assets ....................................................................................... 7 4.2.1. Strategic